ArticleFrontiers in immunology2026
Survival outcomes of intensity-modulated radiotherapy combined with immunotherapy and targeted therapy for hepatocellular carcinoma with classification I-IV portal vein tumor thrombus: a propensity score matching study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study aimed to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) combined with immunotherapy and targeted therapy (IT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) classification I-IV. Patients and methods: The study analyzed HCC patients with PVTT who received IMRT combined with immunotherapy and targeted therapy (RT+IT, Results: Following PSM, 97 pairs of participants were matched. In RT+IT, the median OS was longer (27.63 months, 95% CI: 20.00-33.00) compared to IT (17.57 months, 95% CI: 15.20-22.10), with a hazard ratio (HR) of 0.467 (95% CI: 0.323-0.675, Conclusion: IMRT combined with immunotherapy and targeted therapy was associated with improved survival outcomes with a manageable safety profile in HCC patients with PVTT across classification I-IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.